Serum interferon-gamma-induced protein-10 level and gene polymorphism in patients with drug-induced liver injury accompanied by autoimmune phenomena

Ren Shan; Du XiaoFei; Huang YunLi; Huang ChunYang; Zhang XiaoDan; Dan Jing; Chen XinYue

doi:10.3969/j.issn.1001-5256.2020.03.026

Volume 36 Issue 3

Mar. 2020

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2020 > 36(3): 602-607

PDF( 2191 KB)

Serum interferon-gamma-induced protein-10 level and gene polymorphism in patients with drug-induced liver injury accompanied by autoimmune phenomena

DOI: 10.3969/j.issn.1001-5256.2020.03.026

Department of Hepatology and Immunology,Beijing YouAn Hospital,Capital Medical University

Research funding:

Received Date: 2019-10-15
Published Date: 2020-03-20

Abstract

Abstract

Objective To investigate the single nucleotide polymorphism( SNP) and serum expression of interferon-gamma-induced protein 10( IP-10) in patients with drug-induced liver injury accompanied by autoimmune phenomena( AI-DILI). Methods A total of 168 patients with drug-induced liver injury( DILI) who were diagnosed and treated in Beijing YouAn Hospital,Capital Medical University,from October 2016 to June 2019 were enrolled and divided into AI-DILI group( n = 72) and non-AI-DILI group( n = 96). The SNP of IP-10 rs56061981 locus was detected and the serum level of IP-10 was measured. The two groups were compared in terms of IP-10 level and SNP genotype,and their association with the development of AI-DILI was analyzed. Allele frequency was calculated based on genotype results,and the chi-square test was used for Hardy-Weinberg equilibrium analysis. The t-test and the Mann-Whitney U test were used for comparison between two groups; a repeated measures analysis of variance was used for comparison between different time points; the chi-square test or the Fisher's exact test was used for comparison of categorical data between groups. The Pearson correlation analysis was used to investigate correlation. The receiver operating characteristic( ROC) curve was used to analyze the value of baseline IP-10 level in predicting AI-DILI. Results There was a significant difference in the positive rate of autoantibody between the AI-DILI group and the non-AI-DILI group( 91. 67% vs 12. 5%,χ2= 103. 8,P < 0. 05). Compared with the non-AI-DILI group,the AI-DILI group had significantly higher distribution frequency of CC genotype( 77. 78% vs 62. 50%,χ2= 4. 592,P = 0. 03) and frequency of C allele( 86. 11% vs 72. 92%,χ2= 4. 41,P = 0. 04). The AI-DILI group had a significantly higher baseline IL-10 level than the non-AI-DILI group( 627. 99 ± 198. 07 pg/ml vs 378. 13 ± 218. 45 pg/ml,t = 7. 34,P < 0. 05),and baseline IL-10 level was positively correlated with baseline aspartate aminotransferase level and AIH score( r = 0. 67 and 0. 79,both P < 0. 05). At the optimal cut-off value of 527. 03 pg/ml,baseline IP-10 level had a sensitivity of 0. 846,a specificity of 0. 867,and an area under the ROC curve of 0. 832 in predicting AI-DILI. CC genotype combined with a baseline IP-10 level of ≥527. 03 pg/ml had a positive predictive value of 92. 84% and a negative predictive value of 86. 33% in predicting the development of AI-DILI. Conclusion CC genotype of IP-10 rs56061981 is associated with the development of AI-DILI and affects the serum expression of IP-10,and the combination of CC genotype and IP-10 expression has a high value in predicting AI-DILI.
- drug-induced liver injury,
- hepatitis,autoimmunity,
- polymorphism,single nucleotide,
- interferon-gamma-induced protein-10

FullText(HTML)

References(23)

References

[1] KULLAK UBLICK GA,ANDRADE RJ,MERZ M,et al. Drug induced liver injury:Recent advances in diagnosis and risk assessment[J]. Gut,2017,66(6):1154-1164.

[2] DALY AK,DONALDSON PT,BHATNAGAR P,et al. HLA-B*5701 henotype is a major determinant of drug-induced liver injury due to flucloxacillint[J]. Nat Genet,2009,41(7):816-819.

[3] HUSSANI SH,FARRINGTON EA. Idiosyncratic drug-induce liver injury:An update on the 2007 overview[J]. Expert Opin Drug Saf,2014,13(1):67-81.

[4] MONSHI MM,FAULKNER L,JENKINS RE,et al. Human Leukocyte Antigen(HLA)-B(star)57∶01-restricted activation of drug-specific t cells provides the immunological basis for flucloxacillin-induced liver injury[J]. Hepatology,2013,57:727-739.

[5] ANA A,FAVIEL G,CATHERINE B,et al. In silico analysis of HLA associations with druginduced liver injury:Use of a HLA-genotyped DNA archive from healthy volunteers[J]. Genome Med,2012,4:51.

[6] POSADAS S,PICHLER E. Delayed drug hypersensitivity reactions[J]. Ann Intern Med,2007,39(8):683-693.

[7] HAN Y,CHEN J,SHAN J,et al. Value of fumarate hydratase antibody in differential diagnosis of autoimmune hepatitis and drug-induced liver injury[J]. J Clin Hepatol,2019,35(6):1326-1329.(in Chinese)韩莹，陈杰，单晶，等．抗延胡索酸水合酶抗体对自身免疫性肝炎和药物性肝损伤的鉴别诊断价值[J]．临床肝胆病杂志，2019,35(6):1326-1329.

[8] ZHANG YM,SUN WJ,WEN LZ,et al. Clinical features of patients with drug-induced liver injury in China in the last five years[J]. J Clin Hepatol,2018,34(3):562-566.(in Chinese)张艳梅，孙文静，文良志，等．近5年我国药物性肝损伤患者临床特征分析[J]．临床肝胆病杂志，2018,34(3):562-566.

[9] Drug-induced Liver Disease Study Group,Chinese Society of Hepatology,Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol,2015,31(11):1752-1769.(in Chinese)中华医学会肝病学分会药物性肝病学组．药物性肝损伤诊治指南[J]．临床肝胆病杂志，2015,31(11):1752-1769.

[10] ANAN G,BENICHOU C. Causality assessment of adverse reactions todrugs IA novel method based o A the conclusions of international consensus meetings:Application to drug induced liver injuries[J]. J Clin Epidemiol,1993,46(11):1323-1330.

[11] HENNES EM,ZENIYA M,CZAJA AJ,et al. Simplified criteria for the diagnosis of autoimmune hepatitis[J]. Hepatology,2008,48(1):169-176.

[12] European Association for the Study of the Liver. EASL clinical practice guidelines:Drug-induced liver injury[J]. J Hepatol,2019,70(6):1222-1261.

[13] DONG L,BAI J,JIANG X,et al. The gene polymorphisms of IL-8(-251T/A)and IP-10(-1596C/T)are associated with susceptibility and progression of type 2 diabetic retinopathy in northern Chinese population[J]. Eye(Lond),2017,31(4):601-607.

[14] RUSSMANN S,JETTER A,KULLAK GA. Pharmacogenetics of drug-induced liver injury[J]. Hepatology,2010,52:2-10.

[15] GIOVANNI B,ELISABETTA V,VALENTINA B. High expression levels of IP10/CXCL10 are associated with modulation of the natural killer cell compartment in multiple myeloma[J]. Leuk Lymphoma,2017,58(10):2493-2496.

[16] ALI R,SADAF F,SHAGUFTA K,et al. The association of urinary interferon-gamma inducible protein-10(IP10/CXCL10)levels with kidney allograft rejection[J]. Inflamm Res,2017,66(5):425-432.

[17] ANAJALI J,ERIN B,TUGBA MG,et al. TLR9 polymorphism correlates with immune activation,CD4 decline and plasma IP10 levels in HIV patients[J]. BMC Infect Dis,2019,19(1):56.

[18] LIN C,YAN HY,YANG HY,et al. Combination of DESI2 and IP10 gene therapy significantly improves therapeutic efficacy against murine carcinoma[J]. Oncotarget,2017,8(34):56281-56295.

[19] WENNERBERG E,KREMER V,CHILDS R,et al. CXCL10 induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo[J]. Cancer Immunol Immunother,2015,64(2):225-235.

[20] WANG J,VODOVOTZ Y,FAN L,et al. Injury-induced MRP8/MRP14 stimulates IP-10/CXCL10 in monocytes/macrophages[J]. FASEB J,2015,29(1):250-262.

[21] XIE ZY,CHEN EM,OUYANG XX,et al. Metabolomics and cytokine analysis for identification of severe drug-induced liver injurys[J]. J Proteome Res,2019,18(6):2514-252

[22] PASTOR L,CASELLAS A,RUPEREZ M,et al. Interferongamma-inducible protein 10(IP-10)as ascreening tool to optimize human immunodeficiency virus RNA monitoring inresource-limited settings[J]. Clin Infect Dis,2017,65(10):1670-1765.

[23] CHANDRIKA B,PARTHA PM,BHASWATI P. CXCL10 is overexpressed in active tuberculosis patients compared to M. tuberculosis-exposed household contacts[J]. Tuberculosis(Edinb),2018,109:8-16.

Relative Articles

[1]	Yang Xue, Tu RongFang, Yang JinHui. Research advances in drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(3): 509-513. doi: 10.3969/j.issn.1001-5256.2020.03.006
[2]	Zhang Qing, Liu ShouSheng, Sun BaoKai, Zhang Mei, Xin YongNing. Association of peroxisome proliferator-activated receptor gamma coactivator 1 alpha rs8192678 single nucleotide polymorphism with the risk of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(9): 2035-2039. doi: 10.3969/j.issn.1001-5256.2020.09.025
[3]	Yan Qi, Song LiSha, Xin GuiJie. Research advances in liver injury induced by programmed death protein-1 inhibitors[J]. Journal of Clinical Hepatology, 2019, 35(9): 2113-2115. doi: 10.3969/j.issn.1001-5256.2019.09.051
[4]	Ye LiHong, Wang ChongKui, Jin Peng, Zhao LiangLiang, Zhang HaiCong, Liu ZhiQuan, Tang YaFang. Clinicopathological features of drug-induced liver injury or primary biliary cholangitis with vanishing bile duct syndrome[J]. Journal of Clinical Hepatology, 2019, 35(2): 359-363. doi: 10.3969/j.issn.1001-5256.2019.02.023
[5]	Han Ying, Chen Jie, Dan Jing, Liu YanMin, Zhang XiaoDan, Ren MeiXin, Du XiaoFei, Bian XinQu, Liu Dan, Huang YunLi, Huang ChunYang, Liao HuiYu. Value of fumarate hydratase antibody in differential diagnosis of autoimmune hepatitis and drug-induced liver injury[J]. Journal of Clinical Hepatology, 2019, 35(6): 1326-1329. doi: 10.3969/j.issn.1001-5256.2019.06.029
[6]	Liu Qun, Luan GuiPing, Gao Hui, Zhao BenTian, Du ShuiXian, Liu ShouSheng, Xin YongNing. Association of TRIB1 rs2954029 single nucleotide polymorphism with the risk of nonalcoholic fatty liver disease and coronary heart disease[J]. Journal of Clinical Hepatology, 2019, 35(6): 1330-1336. doi: 10.3969/j.issn.1001-5256.2019.06.030
[7]	Ou WeiJie, Lin YeHong, Zhou Qing, Shang TianYu, Lin Su, Zhu YueYong. Association of vitamin D-related gene polymorphisms with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(6): 1308-1312. doi: 10.3969/j.issn.1001-5256.2019.06.025
[8]	Yu LeCheng, Fan Ye, Chen ChengWei. Diagnosis and treatment of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2018, 34(6): 1160-1165. doi: 10.3969/j.issn.1001-5256.2018.06.004
[9]	Liao SongLing, Liu ShouSheng, Wang Cong, Chen LiZhen, Xin YongNing, Xuan ShiYing. Association between MBOAT7 rs641738 polymorphism and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(10): 2169-2174. doi: 10.3969/j.issn.1001-5256.2018.10.021
[10]	Yue HaiYan, Liu ShouSheng, Wang Cong, Gu JiuLian, Xin YongNing, Xuan ShiYing. Association between single nucleotide polymorphism of low-density lipoprotein receptor and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(9): 1929-1935. doi: 10.3969/j.issn.1001-5256.2018.09.021
[11]	Zhang Hua, He DeHua, Li GuiZhong. Association between single nucleotide polymorphism of microRNA-146a and recurrence after liver cancer surgery[J]. Journal of Clinical Hepatology, 2016, 32(5): 904-907. doi: 10.3969/j.issn.1001-5256.2016.05.018
[12]	Li Long, Wu ZhangHui, Wei Jia. Research progress in association between interleukin 28B gene polymorphism and hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(11): 1916-1920. doi: 10.3969/j.issn.1001-5256.2015.11.040
[13]	Dong QuanYong, Xu Xin, Li JiangWen, Jiang Man, Lin ZhongHua, Chu LeiLei, Xin YongNing, Xuan ShiYing. Association between GCKR gene rs780094( C > T) polymorphism and non- alcoholic fatty liver disease in Han population in Qingdao,China[J]. Journal of Clinical Hepatology, 2015, 31(7): 1092-1095. doi: 10.3969/j.issn.1001-5256.2015.07.022
[14]	Liu Yang, Jiang Man, Chen LiZhen, Du ShuiXian, Xin YongNing, Xuan ShiYing. Association between AGTR1 gene polymorphism and risk of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2015, 31(7): 1082-1087. doi: 10.3969/j.issn.1001-5256.2015.07.020
[15]	Tan GuoLei, Sun Mei, Wang JianFang, Wu XuPing. Relationship between IL- 28B polymorphisms and susceptibility to hepatitis C among Han population in Jiangsu Province, China[J]. Journal of Clinical Hepatology, 2014, 30(6): 514-517. doi: 10.3969/j.issn.1001-5256.2014.06.009
[16]	Wu HaiQing, Zhao GangDe, Li FengDi, Liu KeHui, Xu YuMin, Lin LanYi, Xie Qing, Wang Hui. Association between IPS- 1 polymorphisms and PEG- IFN treatment response in patients with HBeAg- positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2014, 30(8): 757-763. doi: 10.3969/j.issn.1001-5256.2014.08.015
[17]	Niu TongHong, Zhang Mei, Jiang Man, Xin YongNing, Xuan ShiYing. Research advances in gene polymorphisms in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2013, 29(12): 947-951. doi: 10.3969/j.issn.1001-5256.2013.12.020
[18]	Xu Jing, Xin YongNing, Xuan ShiYing. Polymorphisms in PNPLA3 gene is associated with non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2012, 28(4): 316-320.
[19]	Zhou Li, Qie ChunHua, Guo Jie, Lu Wei, Wang Yi, Gao Min, Lu ChengZhen, Han Xu, Zhai Lu. Association between the type Ⅰinterferon receptor promoter gene and treatment response to antivirus in patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2012, 28(5): 352-355.
[20]	Wang JiaSen, Yao DingKang. Value of autoantibodies in predicting autoimmune liver disease[J]. Journal of Clinical Hepatology, 2011, 27(3): 333-336.

Supplements(0)

Cited By

Cited by

Periodical cited type(5)

1.	蔡静，周桂琴，曹亦楠，刘亚兴，王晓静，冯颖，王宪波. 247例中草药相关肝损伤伴或不伴自身抗体阳性患者临床特征对比分析. 中西医结合肝病杂志. 2023(04): 303-306+310 .
2.	刘海涛，张雷鸣，李经纬. 药物性肝损伤患者临床与病理学特征分析. 实用肝脏病杂志. 2022(04): 508-511 .
3.	尹金燕. 浅析药物性肝损伤患者检测自身免疫性抗体的临床价值. 中国实用医药. 2021(07): 77-79 .
4.	张雨，邵玥明，秦婷婷，殷鑫，温晓玉. 细胞因子在药物性肝损伤中的研究现状及应用价值. 临床肝胆病杂志. 2020(08): 1883-1886 . 本站查看
5.	石彩歌，肖奇志，黄士荷，张素粉，王群慧，陈兴，聂继跃，郭天棋. MCA在IFN-α和TNF-β基因多态性检测中的临床应用. 中国卫生标准管理. 2020(16): 103-107 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1258) PDF downloads(222)

Serum interferon-gamma-induced protein-10 level and gene polymorphism in patients with drug-induced liver injury accompanied by autoimmune phenomena

DOI: 10.3969/j.issn.1001-5256.2020.03.026